Sonal Kansra
Research Subjects
Sonal Kansra has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Eishaan Bhargava
1 shared publicationKatherine Whitcroft
1 shared publication- Kofi Cox
St. George’s University of London
1 shared publication - Luca Cox
Faculty of Health University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust. Crookesmoor, England UK
1 shared publication - Susanne Weise
Smell & Taste Clinic, Department of Otorhinolaryngology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Olfactory Function in Cystic Fibrosis - Outcome Measures, Olfactory Dysfunction Prevalence and Management Impact, a Systematic Review
Background: Olfactory dysfunction (OD) is an increasingly recognised but under investigated comorbidity of cystic fibrosis (CF). The prevalence, assessment methods, and management impact of OD in CF remain poorly characterised. Methods: PRISMA 2020-compliant systematic review; PROSPERO ID: CRD420251060317. Databases searched May 2025 (primary) and December 2025 (secondary). Inclusion: confirmed CF diagnosis, peer-reviewed publication, olfactory outcomes reported, English language. Joanna Briggs Institute critical appraisal was used. Narrative synthesis was the primary method; a pre-specified exploratory random-effects prevalence meta-analysis (DerSimonian–Laird; Freeman–Tukey sensitivity analysis) with adult/paediatric subgroup analysis was conducted. Results: 29 papers (21 unique study populations) were included. 15 distinct assessment instruments were identified. Exploratory meta-analysis: pooled OD prevalence 58.9% (95% CI 44.6–72.3%; I²≈90–95%). Adults: 69.7% (95% CI 59.0–79.0%); paediatric: 29.8% (95% CI 13.5–51.7%). Pooled Sniffin’ Sticks Test score was 25.1± 5.6 versus normative 35.0 ± 4.2 (Cohen's d=2.51; hyposmic range). Pooled SNOT-22 was 41.2 ± 18.2 (moderate-to-severe disease). Pooled Lund-Mackay Score was 13.3 ± 5.0 (55.4% of maximum), indicating moderate-to-severe sinonasal burden. Highly effective modulator therapy consistently improved radiological markers of sinonasal disease; HRQoL improvement was variable and did not reach statistical significance in most studies. Psychophysical olfactory scores did not significantly improve in any included study. Conclusions: OD is prevalent and clinically significant in people with CF, with prevalence increasing with age. Heterogeneity in assessment methods limits inter-study comparability. Standardised multidimensional psychophysical testing and integration of olfactory screening into routine CF care are recommended. Prospective longitudinal studies, particularly commencing in childhood, are needed.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessOlfactory Function in Cystic Fibrosis - Outcome Measures, Olfactory Dysfunction Prevalence and Management Impact, a Systematic Review
Background: Olfactory dysfunction (OD) is an increasingly recognised but under investigated comorbidity of cystic fibrosis (CF). The prevalence, assessment methods, and management impact of OD in CF remain poorly characterised. Methods: PRISMA 2020-compliant systematic review; PROSPERO ID: CRD420251060317. Databases searched May 2025 (primary) and December 2025 (secondary). Inclusion: confirmed CF diagnosis, peer-reviewed publication, olfactory outcomes reported, English language. Joanna Briggs Institute critical appraisal was used. Narrative synthesis was the primary method; a pre-specified exploratory random-effects prevalence meta-analysis (DerSimonian–Laird; Freeman–Tukey sensitivity analysis) with adult/paediatric subgroup analysis was conducted. Results: 29 papers (21 unique study populations) were included. 15 distinct assessment instruments were identified. Exploratory meta-analysis: pooled OD prevalence 58.9% (95% CI 44.6–72.3%; I²≈90–95%). Adults: 69.7% (95% CI 59.0–79.0%); paediatric: 29.8% (95% CI 13.5–51.7%). Pooled Sniffin’ Sticks Test score was 25.1± 5.6 versus normative 35.0 ± 4.2 (Cohen's d=2.51; hyposmic range). Pooled SNOT-22 was 41.2 ± 18.2 (moderate-to-severe disease). Pooled Lund-Mackay Score was 13.3 ± 5.0 (55.4% of maximum), indicating moderate-to-severe sinonasal burden. Highly effective modulator therapy consistently improved radiological markers of sinonasal disease; HRQoL improvement was variable and did not reach statistical significance in most studies. Psychophysical olfactory scores did not significantly improve in any included study. Conclusions: OD is prevalent and clinically significant in people with CF, with prevalence increasing with age. Heterogeneity in assessment methods limits inter-study comparability. Standardised multidimensional psychophysical testing and integration of olfactory screening into routine CF care are recommended. Prospective longitudinal studies, particularly commencing in childhood, are needed.